MLLT3 and acute myeloid leukemia: Importantly, Hoxa9-deficient MLL-AF9 cells were highly sensitive to olaparib treatment, highlighting the role of HOXA9 in leukemic growth and the resistance of the MLL-rearranged AML cells to PARP inhibition (Esposito et al., 2015).